- Mark Baum is the CEO of San Diego drug maker Imprimis Pharmaceuticals
- Wants to launch a version of the EpiPen under $100 by the end of the year
- Current maker Mylan has taken price from below $100 to more than $600
- Mylan responded to outcry with $300 generic version of life-saving device
- But Baum says one mg of main ingredient epinephrine costs a few bucks
- EpiPens contain up to 0.3 mg of epinephrine – less than three times that
The key ingredient of an EpiPen costs less than a Big Mac, according to a pharmaceuticals boss.
Mark Baum, the CEO of San Diego-based drug maker Imprimis Pharmaceuticals, hopes to launch a discounted version of the life-saving device by the end of the year.
Baum believes it is possible to sell an EpiPen – and profit from the sale – for less than $100.
Current EpiPEn manufacturer Mylan has raised the price from less than $100 to more than $600 since 2007, drawing outrage from parents, politicians and consumer groups.